Safety and immunogenicity of Salmonella typhi Ty21a vaccine in young Thai children

S J Cryz Jr; N Vanprapar; U Thisyakorn; T Olanratmanee; G Losonsky; M M Levine; S Chearskul

doi:10.1128/iai.61.3.1149-1151.1993

Safety and immunogenicity of Salmonella typhi Ty21a vaccine in young Thai children

Infect Immun. 1993 Mar;61(3):1149-51. doi: 10.1128/iai.61.3.1149-1151.1993.

Authors

S J Cryz Jr¹, N Vanprapar, U Thisyakorn, T Olanratmanee, G Losonsky, M M Levine, S Chearskul

Affiliation

¹ Swiss Serum and Vaccine Institute, Berne.

Abstract

Salmonella typhi Ty21a vaccine in a liquid formulation was evaluated in 634 Thai children 2 to 6 years of age. The seroconversion rate was 69% for those who received vaccine versus 14% for those who received placebo (P < 0.005). The immune responses among vaccine recipients ranged from 60% in 3-year-olds to 81% for 6-year-olds.

Publication types

Clinical Trial
Randomized Controlled Trial

MeSH terms

Age Factors
Antibodies, Bacterial / biosynthesis
Child, Preschool
Humans
Immunoglobulin G / immunology
Lipopolysaccharides / immunology
Salmonella typhi / immunology*
Thailand
Typhoid Fever / prevention & control
Typhoid-Paratyphoid Vaccines / immunology*
Typhoid-Paratyphoid Vaccines / standards
Vaccination

Substances

Antibodies, Bacterial
Immunoglobulin G
Lipopolysaccharides
Typhoid-Paratyphoid Vaccines